Attovia Therapeutics Inc. (ATTO)
ATTO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ATTO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0002058707 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $115.4M cash; operating cash flow -$20.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 45,712,536 (2026-10-31). | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-08-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $42.1M, sold $2.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$22.3M | -$25.7M | $115.4M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $450K | -$20.7M | Not filed | $32.8M | No debt tags | Needs four quarters | 10-Q 2026-09-02 |
| Q3 2026 2026-03-31 | Not filed | -$18.7M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q3 2026 2025-09-30 | $360K | -$13.8M | -$15.2M | $49.8M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2025-06-30 | $0 | -$14.4M | Not filed | $42.6M | No debt tags | Needs four quarters | 10-Q 2026-09-02 |
| Q3 2026 2025-03-31 | Not filed | -$15.2M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-08-05 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
Source: SEC EDGAR submissions feed, 61 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.9% |
| 1 month | +2.8% |
| 3 months | -21.1% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -40.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DBVT | DBV Technologies S.A. | $10.27 | -6.76% | $645.8M |
| BBTX | Bambusa Therapeutics Inc. | $15.98 | -0.68% | $645.4M |
| FDMT | 4D Molecular Therapeutics Inc. | $11.29 | -7.69% | $636.5M |
| SLDB | Solid Biosciences Inc. | $6.48 | -5.26% | $723.2M |
| CGEM | Cullinan Therapeutics Inc. | $9.50 | -7.59% | $616.7M |
| SRZN | Surrozen Inc. | $32.32 | +2.25% | $616.1M |
| AURA | Aura Biosciences Inc. | $7.22 | +1.55% | $751.4M |
| PRME | Prime Medicine Inc. | $4.19 | -1.87% | $762.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier